Feds charge Indivior with fraud, citing $3B scheme to pump up Suboxone sales

courthouse
The Department of Justice unveiled an indictment for U.K.-based Indivior on claims of fraudulent marketing and more. (Pixabay)

Indivior lied and cheated its way to billions of dollars in Suboxone sales, according to a new federal indictment that details a yearslong marketing scheme to pump up sales.

Prosecutors are eyeing a $3 billion judgment in the case, which alleges that Indivior exaggerated the benefits of Suboxone Film, a new version of its older opioid dependence pill. The drugmaker generated billions of dollars by “deceiving" doctors into "believing that Suboxone Film is safer and less susceptible to diversion and abuse than other, similar drugs,” the indictment states.

Indivior also used underhanded tactics to move patients to the film formulation, the indictment states. The company developed Suboxone Film around 2007 as its patent protections for the original tablet were running out, and then, without any evidence to support its claims, marketed Suboxone Film as safer and less prone to child exposure, the government alleges.

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

Next, to delay generic versions of the tablet and switch patients to the film, Indivior withdrew the pill on false concerns of exposure to children, the indictment says.

The company also set up an internet and telephone program for patients to connect with doctors about their opioid dependence, the government says. Indivior intentionally matched those patients with doctors who were prescribing Suboxone in a “careless and clinically unwarranted manner," the indictment alleges.

Authorities are demanding $3 billion for the company’s alleged illicit marketing, plus forfeiture of Indivior assets such as bank accounts and patents. The government alleges health care fraud, wire fraud and mail fraud, along with conspiracy to commit each of those crimes.

Indivior responded in a statement that it's “extremely disappointed” by the indictment, arguing the allegations are “wholly unsupported by either the facts or the law.” 

“The department has apparently decided it would rather pursue self-serving headlines on a matter of national significance than achieve an appropriate resolution, but we will contest this case vigorously and we look forward to the full facts coming out in court,” the company said.

RELATED: Indivior faces huge sales loss as Suboxone court loss puts generics on tap next week 

And in an open letter, Indivior Chairman Howard Pien wrote that the company "never deliberately diverted" its drug. He said governmental agencies have concluded that Suboxone Film's unit-dose packaging are less susceptible to child exposure.

"I couldn’t be prouder of the work Indivior does to fight the opioid crisis," Pien added. "The company conducts more research into opioid addiction than any other company, and the products it has brought to market have helped millions of people struggling with opioid addiction."

The indictment comes only months after Indivior lost U.S. market exclusivity for Suboxone Film. The company has a contingency plan and hopes to bolster its newer launches buprenorphine injection Sublocade and schizophrenia med Perseris while cutting costs.

Still, the Suboxone sales erosion paired with a federal indictment could prove a serious challenge for the drugmaker. Sublocade sales only came in at $12 million last year, while Perseris just launched in February. Last year, Indivior generated just over $1 billion in global sales for all its meds.  

Aside from the Department of Justice investigation and patent challenges with Suboxone, Indivior has faced a number of legal issues in recent years. The Federal Trade Commission is still investigating the drugmaker, according to its annual report. In addition, numerous plaintiffs have sued, claiming the company illegally blocked generic versions of Suboxone tablets. Connecticut and California have each subpoenaed the company, and Indivior is part of a national opioid class action lawsuit. 

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.